BMRN
Companies
NASDAQ
BioMarin Pharmaceutical Inc.
Health Care
$55.24
-$10.49 (-15.96%)
Price Chart
Overview
About BMRN
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Market Cap
$15.3B
Volume
114.5M
Avg. Volume
106.1M
P/E Ratio
20.043478
Dividend Yield
0.00%
Employees
3.7K
Company Information
Risk & Correlation Analysis
Market Correlation
0.61
Low Correlation
Volatility
Medium (0.31)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BMRN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$15.3B
Volume114.5M
P/E Ratio20.04
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
August 4, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025